Iontophoresis
Electrical-field-driven transdermal delivery for enhanced penetration of charged peptide bioregulators.
Electrical-field-driven transdermal delivery for enhanced penetration of charged peptide bioregulators.
Full mechanistic definition forthcoming.
A documented format in pharmaceutical practice.
Historical timeline of the delivery format in the pharmaceutical literature — first characterization, commercial precedents, decades of regulatory-approved use — forthcoming.
How the format delivers.
Absorption pathway, bioavailability characteristics, first-pass metabolism considerations, onset and duration profiles — forthcoming.
Bioregulators formulated for this platform.
Bioregulator compounds with appropriate ionization profiles for electrically driven transdermal delivery.
See the full bioregulator class and the per-compound published literature for compound-specific research references.
Classification and oversight.
OTC device classification; cosmetic (MoCRA) for compatible peptide formulations.
Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.
The format in the scientific literature.
PubMed-indexed peer-reviewed references establishing the format as legitimate pharmaceutical science — forthcoming.
The Atumnus Iontogenix™ platform.
The Iontogenix™ platform is the Atumnus patent-pending embodiment of Iontophoresis. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.
The Iontogenix™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.
Adjacent delivery formats.
Within the same cluster (Topical and Transdermal Delivery), see the full set of delivery platforms in this category.